The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2023

Filed:

Sep. 09, 2019
Applicants:

David A. Scheinberg, New York, NY (US);

Michael R. Mcdevitt, New York, NY (US);

Christophe Antczak, Arlington, MA (US);

Debjit Chattopadhyay, Pennington, NJ (US);

Rena May, Baltimore, MD (US);

Jon Njardarson, Tucson, AZ (US);

Mark Reid Phillips, New York, NY (US);

Inventors:

David A. Scheinberg, New York, NY (US);

Michael R. McDevitt, New York, NY (US);

Christophe Antczak, Arlington, MA (US);

Debjit Chattopadhyay, Pennington, NJ (US);

Rena May, Baltimore, MD (US);

Jon Njardarson, Tucson, AZ (US);

Mark Reid Phillips, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/52 (2017.01); A61K 39/385 (2006.01); A61K 47/64 (2017.01); A61K 47/65 (2017.01); A61K 51/12 (2006.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01); C01B 32/174 (2017.01); A61K 47/69 (2017.01); C01B 32/176 (2017.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 47/52 (2017.08); A61K 39/385 (2013.01); A61K 47/64 (2017.08); A61K 47/65 (2017.08); A61K 47/6925 (2017.08); A61K 51/1248 (2013.01); A61K 51/1275 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01); C01B 32/174 (2017.08); C01B 32/176 (2017.08); B82Y 5/00 (2013.01); C01B 2202/02 (2013.01); C01B 2202/28 (2013.01); C01B 2202/34 (2013.01); C01B 2202/36 (2013.01);
Abstract

The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.


Find Patent Forward Citations

Loading…